AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34863260 — intervention group
Group type: COMPARATOR
Intervention: Sugared chewing gum containing Maltitol (23% w/v)
Number of subjects: 0
Study 34863270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound therapy
Number of subjects: 500
Study 34863270 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured counseling
Number of subjects: 500
Study 34863270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 500
Study 34863270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Number of subjects: 500
Study 34863270 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of therapies
Number of subjects: 500
Study 34863273 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual pilot PCOR training program
Number of subjects: 59
Study 34863908 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAp at 48 hours
Number of subjects: 112
Study 34863908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau at 48 hours
Number of subjects: 112
Study 34863908 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAp AUROC at 48 hours
Number of subjects: 112
Study 34863908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau AUROC at 48 hours
Number of subjects: 112
Study 34863908 — intervention group
Group type: COMPARATOR
Intervention: NSE AUROC at 48 hours
Number of subjects: 112
Study 34863908 — intervention group
Group type: EXPERIMENTAL
Intervention: GFAp AUROC at 72 hours
Number of subjects: 112
Study 34863908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau AUROC at 72 hours
Number of subjects: 112
Study 34863908 — intervention group
Group type: COMPARATOR
Intervention: NSE AUROC at 72 hours
Number of subjects: 112
Study 34864079 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe obesity (BMI ≥35 kg/m²)
Number of subjects: 1005
Study 34864079 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 1005
Study 34864079 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade-I obesity
Number of subjects: 1005
Study 34864079 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight
Number of subjects: 1005
Study 34864079 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe obesity without CV risk factors
Number of subjects: 1005
Study 34864316 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings of control over pregnancy (survey statement: 'I feel that I have control over whether or not I get pregnant')
Number of subjects: 2594
Study 34864316 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants reporting poverty-level incomes
Number of subjects: 2594
Study 34864316 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with previous unwanted pregnancies
Number of subjects: 2594
Study 34864883 — intervention group
Group type: EXPERIMENTAL
Intervention: Aarau trauma prognostic longer-term outcome scoring (ATPLOS) system
Number of subjects: 1052
Study 34864883 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROM)
Number of subjects: 1052
Study 34864883 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analysis of sociodemographic, injury-related, treatment, and early hospital outcome variables
Number of subjects: 1052
Study 34864917 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 5619
Study 34864930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster A (purely axial)
Number of subjects: 584
Study 34864930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster B (both axial and peripheral)
Number of subjects: 584
Study 34864948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir (90mg/400mg) once daily for 12 weeks
Number of subjects: 111
Study 34864959 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient FH (R-FH) defined by the presence of a pathogenic mutation causative of FH in patients aged ≥65 years without clinical ASCVD.
Number of subjects: 930
Study 34864959 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of HDL-C and lower 10-year score in SAFEHEART-RE.
Number of subjects: 930
Study 34865019 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx) with embryo transfer (ET) attempted 12 months after transplantation.
Number of subjects: 7
Study 34865064 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal SARS-CoV-2 infection
Number of subjects: 87
Study 34865064 — intervention group
Group type: EXPERIMENTAL
Intervention: Time between symptom onset and childbirth
Number of subjects: 87
Study 34865064 — intervention group
Group type: EXPERIMENTAL
Intervention: Older gestational age at birth
Number of subjects: 87
Study 34865064 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal IgG and placental transfer
Number of subjects: 87
Study 34865085 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline, Topiramate, or Placebo (twice daily)
Number of subjects: 328
Study 34865085 — intervention group
Group type: COMPARATOR
Intervention: Serum drug levels
Number of subjects: 328
Study 34865085 — intervention group
Group type: COMPARATOR
Intervention: Self-report and pill count adherence
Number of subjects: 328
Study 34865085 — intervention group
Group type: COMPARATOR
Intervention: Serum drug levels at trial midpoint
Number of subjects: 328
Study 34865186 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype C
Number of subjects: 133
Study 34865186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both phenotypes B and C
Number of subjects: 133
Study 34865212 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent ibrutinib (n=45)
Number of subjects: 89
Study 34865212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with an anti-CD20 antibody (n=44)
Number of subjects: 89
Study 34865212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (ibrutinib alone and in combination)
Number of subjects: 89
Study 34866168 — intervention group
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg orally twice daily
Number of subjects: 0
Study 34866276 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset pain
Number of subjects: 65
Study 34866276 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically significant pain (NRS ≥3)
Number of subjects: 65
Study 34866276 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic pain
Number of subjects: 65
Study 34866276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing thoughts
Number of subjects: 65
Study 34866276 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain in ≥2 body sites
Number of subjects: 65
Study 34866276 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread pain
Number of subjects: 65
Study 34866276 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Related Quality of Life (HRQoL)
Number of subjects: 65
Study 34866276 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood disorders (HADS)
Number of subjects: 65
Study 34866900 — intervention group
Group type: EXPERIMENTAL
Intervention: 550lx illuminance
Number of subjects: 0
Study 34866900 — intervention group
Group type: COMPARATOR
Intervention: 20lx illuminance
Number of subjects: 0
Study 34866900 — intervention group
Group type: EXPERIMENTAL
Intervention: Illuminance requirement
Number of subjects: 0
Study 34867148 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of Val/Met (G/A) or Met (A/A) alleles
Number of subjects: 187
Study 34867148 — intervention group
Group type: COMPARATOR
Intervention: Homozygous Val (G/G) carriers
Number of subjects: 187
Study 34867275 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention for 5 years
Number of subjects: 0
Study 34867275 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cardiorespiratory fitness
Number of subjects: 0
Study 34867468 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34867586 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support
Number of subjects: 0
Study 34867586 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 34867617 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Communication Scale
Number of subjects: 0
Study 34867626 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Meditation
Number of subjects: 0
Study 34867626 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34867691 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrive by Three intervention (10-month, multicomponent, in-service professional development)
Number of subjects: 187
Study 34867691 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 187
Study 34867742 — intervention group
Group type: EXPERIMENTAL
Intervention: active vibrotactile coordinated reset (vCR) stimulation
Number of subjects: 30
Study 34867742 — intervention group
Group type: COMPARATOR
Intervention: inactive (sham) vibrotactile coordinated reset (vCR) stimulation
Number of subjects: 30
Study 34868003 — intervention group
Group type: EXPERIMENTAL
Intervention: XAV-19
Number of subjects: 0
Study 34868050 — intervention group
Group type: EXPERIMENTAL
Intervention: 81mg of ASA daily for 6 weeks
Number of subjects: 0
Study 34868583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 371
Study 34868583 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin
Number of subjects: 371
Study 34868614 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO app
Number of subjects: 44
Study 34868671 — intervention group
Group type: EXPERIMENTAL
Intervention: FS-LASIK surgery
Number of subjects: 30
Study 34868687 — intervention group
Group type: COMPARATOR
Intervention: Bilateral simple orchidectomy (BSO)
Number of subjects: 63
Study 34868687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subcapsular orchidectomy (BSCO)
Number of subjects: 63
Study 34868687 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral-epididymal-sparing orchidectomy (BESO)
Number of subjects: 63
Study 34868736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful yoga intervention
Number of subjects: 0
Study 34868929 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR-ICG imaging
Number of subjects: 51
Study 34868929 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR-ICG imaging combined with WL imaging
Number of subjects: 51
Study 34869421 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying intensity of ventilation
Number of subjects: 0
Study 34869442 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Interferon-Gamma Release Assay
Number of subjects: 0
Study 34869534 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating
Number of subjects: 0
Study 34869534 — intervention group
Group type: EXPERIMENTAL
Intervention: Late Time-Restricted Eating
Number of subjects: 0
Study 34869651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) levels
Number of subjects: 51500
Study 34869651 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated Glomerular Filtration Rate (eGFR) levels
Number of subjects: 51500
Study 34869938 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention including non-hormonal pharmacotherapy for VMS, digital cognitive behavioural therapy for insomnia, self-management strategies, and partner support
Number of subjects: 205
Study 34869938 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention
Number of subjects: 205
Study 34869940 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical education on SCI related topics offered by specialists to GPs practicing in rural areas.
Number of subjects: 395
Study 34869940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 395
Study 34870025 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal plus postnatal small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 80
Study 34870025 — intervention group
Group type: COMPARATOR
Intervention: Prenatal iron and folic acid (IFA) supplementation
Number of subjects: 80
Study 34870071 — intervention group
Group type: EXPERIMENTAL
Intervention: Short food-frequency questionnaire (SFFQ)
Number of subjects: 130
Study 34870071 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive food-frequency questionnaire (CFFQ)
Number of subjects: 130
Study 34870211 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning convolutional neural network (CNN) enhancement of PET/MRI scans
Number of subjects: 20
Study 34870215 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) system applied to digital mammography (DM) examinations
Number of subjects: 14768
Study 34870215 — intervention group
Group type: COMPARATOR
Intervention: Double reading performance
Number of subjects: 14768
Study 34870321 — intervention group
Group type: COMPARATOR
Intervention: Carisbamate
Number of subjects: 2211
Study 34870327 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (active immunotherapy Bacillus Calmette-Guérin (BCG), adoptive cell transfer, transfer factor (TF), tumour-infiltrating lymphocytes (TIL), dendritic cell/cytokine-induced killer (DC/CIK), antigen-specific cancer vaccines (MAGE-A3, L-BLP25), targeted natural killer (NK) cells)
Number of subjects: 5128
Study 34870327 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 5128
Study 34870630 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccines
Number of subjects: 0
Study 34870630 — intervention group
Group type: EXPERIMENTAL
Intervention: V-SAFE technology
Number of subjects: 0
Study 34870789 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1777
Study 34870789 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 1777
Study 34870800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 7844
Study 34870878 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab 750 mg/wk
Number of subjects: 21
Study 34870878 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk
Number of subjects: 21
Study 34870878 — intervention group
Group type: EXPERIMENTAL
Intervention: Xentuzumab 1000 mg/wk (expansion cohort)
Number of subjects: 21
Study 34870940 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective factors (self-efficacy for coping with cancer, spiritual well-being)
Number of subjects: 416
Study 34870940 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 416
Study 34870940 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised resilience model
Number of subjects: 416
Study 34871089 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV) at 25 mg once daily plus two investigator-selected NRTIs
Number of subjects: 0
Study 34871104 — intervention group
Group type: EXPERIMENTAL
Intervention: hu14.18K322A with induction chemotherapy
Number of subjects: 64
Study 34871175 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-controlled pedaling training system (BCI-PT)
Number of subjects: 30
Study 34871175 — intervention group
Group type: COMPARATOR
Intervention: Traditional pedaling training (Control)
Number of subjects: 30
Study 34871178 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention using a virtual reality simulation and a mobile platform for monitoring stress indicators; duration of monitoring is 8 weeks.
Number of subjects: 0
Study 34871178 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention at individual, team, and organizational levels; specific details on dosage and duration not provided.
Number of subjects: 0
Study 34871190 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) from women with severe preeclampsia (sPE)
Number of subjects: 29
Study 34871190 — intervention group
Group type: COMPARATOR
Intervention: Extracellular vesicles (EVs) from normotensive pregnant women
Number of subjects: 29
Study 34871241 — intervention group
Group type: EXPERIMENTAL
Intervention: s-Flt-1 at concentrations greater than 60 pg/ml
Number of subjects: 336
Study 34871241 — intervention group
Group type: EXPERIMENTAL
Intervention: s-Flt-1 at concentrations greater than 70 pg/ml
Number of subjects: 336
Study 34871241 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT with at least 80% decrease or PCT less than 0.5 ng/ml on day 7
Number of subjects: 336
Study 34871308 — intervention group
Group type: EXPERIMENTAL
Intervention: nAb titers measured in serum by SARS-CoV-2.D614G Spike-pseudotyped virus infection of 293T/ACE2 cells
Number of subjects: 329
Study 34871308 — intervention group
Group type: EXPERIMENTAL
Intervention: nAb titers measured in serum
Number of subjects: 329
Study 34871308 — intervention group
Group type: EXPERIMENTAL
Intervention: nAb ID50 (ID80) titers
Number of subjects: 329
Study 34871308 — intervention group
Group type: EXPERIMENTAL
Intervention: nAb titers after SARS-CoV-2 infection
Number of subjects: 329
Study 34871341 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict containment and health policies
Number of subjects: 1256
Study 34871341 — intervention group
Group type: EXPERIMENTAL
Intervention: Less strict policies
Number of subjects: 1256
Study 34871341 — intervention group
Group type: EXPERIMENTAL
Intervention: Very strict policies
Number of subjects: 1256
Study 34871370 — intervention group
Group type: EXPERIMENTAL
Intervention: 20S proteasome
Number of subjects: 9
Study 34871370 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1
Number of subjects: 9
Study 34871371 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor memory-like NK cells
Number of subjects: 9
Study 34871427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorghum diet with lysine levels of 8.2, 12.5, and 15.7 mg.kg-1.d-1
Number of subjects: 5
Study 34871427 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementation diet with lentils
Number of subjects: 5
Study 34871427 — intervention group
Group type: COMPARATOR
Intervention: Reference diet with L-lysine levels of 5, 8, 12, and 15 mg.kg-1.d-1
Number of subjects: 5
Study 34871570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 100 mg
Number of subjects: 60
Study 34871570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 150 mg
Number of subjects: 60
Study 34871570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 200 mg
Number of subjects: 60
Study 34871570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine 300 mg
Number of subjects: 60
Study 34871572 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Rule (DISCERN-FN) applied a posteriori
Number of subjects: 2345
Study 34871698 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma lead concentration
Number of subjects: 670
Study 34871698 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lead concentration at admission for transplant
Number of subjects: 670
Study 34871698 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lead concentration after 3 months post-transplant
Number of subjects: 670
Study 34871924 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOPA-AUT questionnaire
Number of subjects: 70
Study 34871924 — intervention group
Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 70
Study 34872106 — intervention group
Group type: EXPERIMENTAL
Intervention: TCRαβ/CD19-depleted HSCT
Number of subjects: 60
Study 34872515 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard anti-NTM treatment initiated within 3 months after diagnosis of NTM pulmonary disease
Number of subjects: 202
Study 34872515 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT chest images findings in patients with NTM pulmonary disease
Number of subjects: 202
Study 34872515 — intervention group
Group type: COMPARATOR
Intervention: HRCT chest images findings in patients without NTM pulmonary disease
Number of subjects: 202
Study 34872515 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of HRCT features
Number of subjects: 202
Study 34872549 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-item swallowing screen (oral stereognosis and cough-reflex tests)
Number of subjects: 123
Study 34872587 — intervention group
Group type: EXPERIMENTAL
Intervention: Low omega-3 PUFA intake group
Number of subjects: 62
Study 34872587 — intervention group
Group type: EXPERIMENTAL
Intervention: High omega-3 PUFA intake group
Number of subjects: 62
Study 34872604 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO-containing protocol (P1)
Number of subjects: 12
Study 34872604 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO-free protocol (P2)
Number of subjects: 12
Study 34872604 — intervention group
Group type: COMPARATOR
Intervention: Open vitrification system
Number of subjects: 12
Study 34872604 — intervention group
Group type: COMPARATOR
Intervention: Closed vitrification system
Number of subjects: 12
Study 34872617 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive BP lowering to a target systolic BP of < 140 mmHg within 30 min
Number of subjects: 3116
Study 34872617 — intervention group
Group type: COMPARATOR
Intervention: guideline-recommended BP management according to local protocols
Number of subjects: 3116
Study 34872619 — intervention group
Group type: EXPERIMENTAL
Intervention: E3 webinar-based training
Number of subjects: 0
Study 34872619 — intervention group
Group type: EXPERIMENTAL
Intervention: E3 webinar plus consultation
Number of subjects: 0
Study 34872619 — intervention group
Group type: COMPARATOR
Intervention: Delayed training
Number of subjects: 0
Study 34873004 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of labour offered to women with internal-os-distance >5 mm
Number of subjects: 30
Study 34873004 — intervention group
Group type: COMPARATOR
Intervention: Women with normally located placenta
Number of subjects: 30
Study 34873092 — intervention group
Group type: EXPERIMENTAL
Intervention: Steatosis (n=30)
Number of subjects: 82
Study 34873092 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosis (n=22)
Number of subjects: 82
Study 34873092 — intervention group
Group type: COMPARATOR
Intervention: Normal (n=30)
Number of subjects: 82
Study 34873185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulus
Number of subjects: 0
Study 34873185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnic stimulus
Number of subjects: 0
Study 34873185 — intervention group
Group type: COMPARATOR
Intervention: Short source-detector separation (SDS) channels during cognitive stimulus
Number of subjects: 0
Study 34873185 — intervention group
Group type: COMPARATOR
Intervention: Short source-detector separation (SDS) channels during hypercapnic stimulus
Number of subjects: 0
Study 34873185 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low frequency (VLF) band activity
Number of subjects: 0